We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Celadon Pharmaceuticals Plc | CEL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -3.00 | -13.33% | 19.50 | 14:10:51 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 22.50 | 19.50 | 22.50 | 22.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 17/1/2025 14:44 by jaknife Why so generous?With 68.85m shares in issue ( 15p would value the company at £10.3m. And yet: Balance Sheet The last reported balance sheet was the June interims, which showed net equity of just £2.5m and negligible cash: Post that date they claimed to raise £1.05m at 40p a share in September. Can we be sure that those funds have arrived? There is obviously something skanky about the way that CEL goes about raising funds (relative to the rest of the companies on AIM) as they make gloriously grand announcements about the fund raises but then have to admit, many many months AFTER the date of the announcement, that the funds haven't actually arrived in full! Regardless, let's assume that the full £1.05m did arrive. But they have burnt about £2.5m of cash every six months so where does that put them now? That would imply that net assets decreased by £1.5m as at the end of Dec. Is the balance sheet just a net £1m at year-end? Sales CEL have put out various wild claims of big sales contracts, eg: Inaugural Supply Contract Win which included: "Under the terms of the contract, Celadon will sell a minimum of £3 million worth of product over the next three years, with the first shipment expected in Q4 2023. At the end of the three years, the contract can be extended for a further two years with the mutual agreement of the parties." And yet I refer you again to the interims that show revenues of just £63k for the first six months of 2024! Surely £3m over 3 years means £500k every six months? Did they lie in the original RNS? Or is there a problem? In which case why haven't they updated the market and explained? conclusion Frankly Celadon looks an awful business. The directors have published numerous RNSs that we can now objectively demonstrate with hindsight were either completely untrue or contained wildly optimistic unstated assumptions. How can we trust *ANY* RNS that they publish? They are burning £2.5m every six months and reported on 2 January that they only had enough cash to keep them going to the end of March. Obviously they need to raise funds. If they want to keep going for at least a year then they should raise a minimum of £5m (or else massively cut their cost base). But frankly I value this company at no more than its net assets, which I estimate is about £1m and hence if they raise at more than 1.5p then that would be excessively generous! JakNife |
Posted at 23/8/2024 15:10 by citys2874 would love CEL and URU to finish top number 1 and number 2 on leaderboard today |
Posted at 23/8/2024 15:09 by citys2874 CEL up 70 percent nice |
Posted at 23/8/2024 14:41 by citys2874 check out URU could well be a tripple bagger, worth buying a few today, fab day so far for Both CEL and URU |
Posted at 12/8/2024 08:31 by jaknife Celadon informs the market that:1. It hasn't received all of cash from the May placing (three months after!), 2. It hasn't received the cash from the loan announced in May, and 3. It only has £48k of cash left before it's lights off time |
Posted at 03/7/2024 09:50 by jaknife talk2dubya,"Well the facilities alone are worth 60m. Nice update" I'm afraid that whomever told you that was taking advantage of your naivety. The accounts are quite clear: CEL has invested less than £3m into its "facilities", which are loss-making. JakNife |
Posted at 10/5/2024 06:59 by czar These new investors want in to CEL and are happy to pay the offer price, that speaks volumes for what they know about this business. |
Posted at 16/11/2023 16:18 by czar Take a look back at GW Pharma they were a penny stock on AIM that followed the same path as Celadon and sold for $7.2b $220 a share. CEL will emulate GW, maybe not $220 a share but many many times the current price IMHO. |
Posted at 16/11/2023 07:33 by ahhh luke warm London, 16 November 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, announces that it has entered into a contract for the commercial supply of its pharmaceutical-grade cannabis product with a leading European medicinal cannabis company.The contract has the potential to generate revenue to Celadon of up to GBP26 million of product (GBP8.7 million annually) over the three year term, with the first delivery anticipated in H2 2024. The two parties retain the option to extend the contract for a further two years by mutual agreement.This latest sales contract follows the two previous UK contracts announced in May and September 2023 respectively. |
Posted at 14/3/2023 15:42 by oakridge Some thoughts on CEL and HELD (from the HELD thread) below.(Don't forget CEL possibly need a cash injection so don't get greedy on the spike!) Oakridge14 Mar '23 - 15:20 - 480 of 481 Edit 0 1 0 News out at CEL. Great news for the cannabis space. What we can say is that CEL, or, those involved in the work around this RNS = a leaky ship! Including that big volume spike / buy a few weeks ago. Naughty! Oakridge14 Mar '23 - 15:40 - 481 of 481 Edit 0 0 0 It's important to watch the reaction at CEL, and particularly the rocket that has been put under the companies share price over recent days. The home office has now extended their license so that they can enter into commercial (non research) agreements to sell a high THC content product to third parties and are the first UK based pharmaceutical facility / cultivators in the UK to do this. They say: "Within the UK, patients prescribed medicinal cannabis are reliant on imported product, often facing lengthy delays and high costs, and by becoming a UK-based producer, Celadon is in a prime position to alleviate the issues currently faced by patients." Well, it's going to be interesting to see what price-point CEL can come in at and maintain. They've already announced that expansion into their second growing room had to delayed this year by spiralling costs we have all grown so familiar with. Their facilities are, I think, only around 10% of HELD's entire license. I'll check on that. So, whilst they may be first over the line and should be congratulated, the scale of their operations, at present, is a fraction of what HELD have been granted in Greece. CEL are also operating from a country with considerably higher costs. Current mkt cap: £265M HELD: c.£11M. HELD still have work to do, but should, all being well, be rubber stamped and selling product at around the end of Q2. AIMO ADYOR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
